Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Vector Laboratories has added to its mouse-on-mouse (MOM) family of detection reagents the MOM ImmPress peroxidase polymer kit. It allows the use of mouse primary antibodies on mouse tissue without background staining, by using a sensitive, one-step, non-biotin MOM ImmPress polymer reagent. The reagent also provides a time savings in the detection protocol, since it is ready to use in one step.
MidSci’s Bio-Assembler kits use magnetic levitation to culture cells in three dimensions. Available in single-, six-, and 24-well configurations, the kits supply magnetic drivers, low-binding dishes/ plates, and Nanoshuttle-PL solution in quantities and volumes appropriate to kit size.
Sarstedt’s S-Monovette is an enclosed multiple-sampling blood collection system. All tubes are plastic and have screw caps, which minimizes the risk of breakage and aerosol formation when caps are removed. The screw caps have a thin, recessed membrane that is easy to puncture and protects users from residual blood droplets.
Trovagene expects to achieve analytical and clinical validation of its urine-based HPV carrier screening test this month in its CLIA laboratory. When validation is complete, the test will be available to clinicians and their patients.
Selventa’s Systems Diagnostics, or SysDx, will be a novel class of diagnostic tests that consist of “multi-omic” biomarkers selected through analysis of a patient’s biological profile, including genomic, epigenomic, transcriptomic, proteomic, metabolomic, and electronic medical record information. From the data, Selventa will generate a differentiated and clinically relevant report that physicians and patients can use to improve therapy selection.
Hardy Diagnostics’ Arcanobacterium selective agar is a selective medium for the isolation of Arcanobacterium haemolyticum, especially from respiratory specimens.
Spot Imaging Solutions’ ultrasensitive Spot Pursuit USB digital camera combines superb image quality with excellent temporal resolution for rapid time-lapse recordings. This enables researchers to document live cells and photobleaching fluorescence specimens easily.
Thermo Fisher Scientific has expanded its suite of cryopreservation reagents with the HyClone HyCryo and HyCryo-Stem cryopreservation media, enabling researchers to maximize the preservation, recovery, and growth of post-thaw cells for general cell culture and stem-cell applications.
Alpha-Tec Systems’ NAC-PAC (Nacetylcysteine-package) EA3 offers a complete specimen preparation reagent system to digest, buffer, and resuspend patient samples for lab analysis of Mycobacterium spp. The reagents in NAC-PAC EA3 improve the efficiency of acid-fast bacilli diagnostics and reduce the need to reprocess samples by controlling pH throughout the entire specimen preparation procedure with an integrated pH indicator to ensure a neutral patient sample is achieved.
Dako recently introduced in the United States its instant quality in situ hybridization, or IQISH, technology, which will reduce the turnaround time for cancer evaluation from two days to three and a half hours. HER2 IQFISH PharmDx, a fluorescence in situ hybridization assay, is the first product approved by the FDA that uses IQISH technology, which is based on the company’s fast IQISH hybridization buffer chemistry.
